| Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. | |
| | |
MedLine Citation:
|
PMID: 18854619 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of 13-cis retinoic acid (13-cis RA) for improving I-131 uptake in recurrent or metastatic of DTC with defective I-131 uptake. Eleven patients (Age 27-66 years, M : F=4 : 7) were given 13-cis RA (1.5 mg/kg daily for 5 weeks), followed by 200 mCi (7.4 GBq) I-131 treatment. The differences of serum thyroglobulin (Tg) level and I-131 uptake on the post-treatment whole body scan (RxWBS) were compared before and after 13-cis RA therapy. Six out of 11 patients showed significantly increased (above 50%) Tg levels just after RA therapy. However, Tg levels a year after I-131 therapy were increased, stable and decreased in 7, 2 and 1 patients, respectively. Iodine uptake on RxWBS showed marginal improvement in only 2 patients and their Tg levels after one year follow-up increased. Most frequent adverse events were dry skin and lips. 13-cis RA partially restores I-131 uptake in few patients with recurrent or metastatic DTC. The use of 13-cis RA in current protocol has only limited usefulness and is not routinely recommended as currently used protocol. |
| | |
Authors:
|
Won Gu Kim; Eui Young Kim; Tae Yong Kim; Jin-Sook Ryu; Suck Joon Hong; Won Bae Kim; Young Kee Shong |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-10-11 |
Journal Detail:
|
Title: Endocrine journal Volume: 56 ISSN: 1348-4540 ISO Abbreviation: Endocr. J. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-03-13 Completed Date: 2009-04-21 Revised Date: 2011-06-16 |
Medline Journal Info:
|
Nlm Unique ID: 9313485 Medline TA: Endocr J Country: Japan |
Other Details:
|
Languages: eng Pagination: 105-12 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology & Metabolism, University of Ulsan College of Medicine, Seoul, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / adverse effects, pharmacology, therapeutic use Carcinoma, Papillary, Follicular / drug therapy*, radiotherapy* Cell Differentiation* / drug effects Chemotherapy, Adjuvant / methods Combined Modality Therapy Female Humans Iodine Radioisotopes / therapeutic use Isotretinoin / adverse effects, pharmacology, therapeutic use* Male Middle Aged Radiotherapy Dosage Thyroid Neoplasms / drug therapy*, radiotherapy* Treatment Failure Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Iodine Radioisotopes; 4759-48-2/Isotretinoin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sig...
Next Document: Barrett's esophagus and severe reflux esophagitis share common pathophysiological characteristics am...